The University of Pittsburgh Multicenter AIDS Cohort Study (Pitt MACS) Clinical Research Site (CRS) was established in 1983 by Dr. C. Rinaldo, PI, as one of 4 MACS CRS as a prospective cohort study of the natural history of HIV infection and the impact of effective combination antiretroviral therapies (cART) in men who have sex with men (MSM). We will continue to combine genetic, virologic, immunologic and psychosocial approaches and utilize the specimen cryorepository for long-term characterization of Pitt MACS participants. Along with our new satellite clinic site at The Ohio State University (OSU) led by Dr. S. Koletar, we will continue follow-up of the cohort with a dynamic enrollment to enable further elucidation of the biology and response to HIV infection, and distinguishing the effects of age, HIV, evolving cART regimens, genetics, co- infections and behavior use on clinical outcomes and causally-associated biomarkers. This is a transition to a rolling cohort design to replace existing cohort members who die or otherwise are permanently lost to follow-up. The Pitt MACS scientific agenda focuses on clinical epidemiology, pathogenesis, psychosocial factors, and development of novel methods for the study of HIV disease. The Pitt MACS is ideally positioned to address these issues because of long-term standardized follow-up, an extensive repository and an appropriate control group of HIV-uninfected MSM with similar lifestyles, behaviors, and demographics. The Pitt MACS contributes strength and innovation in three areas: (a) studies of viral genomics and host immunopathogenesis including HHV-8/KSHV and HCV coinfections and regulation by host microRNAs, (b) in depth analysis of effects of HIV infection in the brain and lungs including microbiome analysis, and (c) studies of syndemics and resiliencies in aging MSM including effects on depression, substance use and sexual behavior. The Pitt MACS CRS will continue to contribute via the MACS Executive Committee and Working Groups with expertise in all aspects of HIV infection to successfully address our 7 scientific aims that are identical to those in Part A. The Pitt MACS will continue to characterize the long-term, natural and treated history of HIV infection in MSM, provide insight into the clinical epidemiology of HIV, and further our understanding of predictors of disease among HIV positive MSM.

Public Health Relevance

The scientific leadership and methods implemented by the Pitt MACS will enable the MACS to answer important questions relevant to treated HIV-infected MSM, the group with the highest HIV incidence in the US, and questions about the interaction of HIV and aging, important as the HIV-infected population shifts into older ages. The proposed research will provide information for development and administration of new interventions for HIV, as well as for the prevention of AIDS-defining and non-AIDS defining outcomes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
2U01AI035041-22
Application #
8699457
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Roe, Joanad'Arc C
Project Start
1993-04-01
Project End
2019-04-30
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
22
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Public Health
DUNS #
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Jotwani, Vasantha; Scherzer, Rebecca; Estrella, Michelle M et al. (2016) Brief Report: Cumulative Tenofovir Disoproxil Fumarate Exposure is Associated With Biomarkers of Tubular Injury and Fibrosis in HIV-Infected Men. J Acquir Immune Defic Syndr 73:177-81
Jotwani, Vasantha; Scherzer, Rebecca; Estrella, Michelle M et al. (2016) HIV Infection, Tenofovir, and Urine α1-Microglobulin: A Cross-sectional Analysis in the Multicenter AIDS Cohort Study. Am J Kidney Dis 68:571-81
Martinez-Picado, Javier; McLaren, Paul J; Erkizia, Itziar et al. (2016) Identification of Siglec-1 null individuals infected with HIV-1. Nat Commun 7:12412
Rebeiro, Peter F; Gange, Stephen J; Horberg, Michael A et al. (2016) Geographic Variations in Retention in Care among HIV-Infected Adults in the United States. PLoS One 11:e0146119
Wada, Nikolas I; Bream, Jay H; Martínez-Maza, Otoniel et al. (2016) Inflammatory Biomarkers and Mortality Risk Among HIV-Suppressed Men: A Multisite Prospective Cohort Study. Clin Infect Dis 63:984-90
Aziz, Najib; Detels, Roger; Quint, Joshua J et al. (2016) Stability of cytokines, chemokines and soluble activation markers in unprocessed blood stored under different conditions. Cytokine 84:17-24
Koethe, John R; Jenkins, Cathy A; Lau, Bryan et al. (2016) Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. AIDS Res Hum Retroviruses 32:50-8
Cesar, Carina; Koethe, John R; Giganti, Mark J et al. (2016) Health outcomes among HIV-positive Latinos initiating antiretroviral therapy in North America versus Central and South America. J Int AIDS Soc 19:20684
Brener, Michael I; Post, Wendy S; Haberlen, Sabina A et al. (2016) Comparison of Insulin Resistance to Coronary Atherosclerosis in Human Immunodeficiency Virus Infected and Uninfected Men (from the Multicenter AIDS Cohort Study). Am J Cardiol 117:993-1000
Rachlis, Beth; Karwa, Rakhi; Chema, Celia et al. (2016) Targeted Spontaneous Reporting: Assessing Opportunities to Conduct Routine Pharmacovigilance for Antiretroviral Treatment on an International Scale. Drug Saf 39:959-76

Showing the most recent 10 out of 483 publications